HC Wainwright Issues Optimistic Outlook for CORT Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Corcept to $0.33 (from $0.24), maintains a Buy rating and a $75 price target, and provided bullish Q3/Q4 2027 EPS forecasts ($0.85/$0.84).
• Corcept missed its most recent quarter, reporting EPS of ($0.30) versus consensus ($0.11) and revenue of $164.9M versus $185.8M, though revenue was up 4.9% year‑over‑year.
• Insider activity: Director G. Leonard Baker Jr. purchased 100,000 shares at about $33.14 in March (≈$3.31M), while CEO Joseph Belanoff sold ~26,198 shares; insiders currently own roughly 20.8% of the stock.

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities research analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for Corcept Therapeutics in a research report issued on Monday, May 4th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will earn $0.33 per share for the quarter, up from their prior forecast of $0.24. HC Wainwright currently has a "Buy" rating and a $75.00 target price on the stock. The consensus estimate for Corcept Therapeutics' current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Corcept Therapeutics' Q3 2027 earnings at $0.85 EPS and Q4 2027 earnings at $0.84 EPS.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.19). The business had revenue of $164.90 million for the quarter, compared to the consensus estimate of $185.83 million. Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The company's revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.17 earnings per share.

A number of other research analysts also recently weighed in on the company. Wolfe Research raised Corcept Therapeutics from an "underperform" rating to a "peer perform" rating in a report on Thursday, March 26th. Canaccord Genuity Group increased their target price on Corcept Therapeutics from $100.00 to $110.00 and gave the company a "buy" rating in a report on Thursday, March 26th. Piper Sandler upped their price target on Corcept Therapeutics from $73.00 to $88.00 and gave the stock an "overweight" rating in a research report on Friday. Zacks Research cut Corcept Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, January 13th. Finally, Truist Financial upgraded Corcept Therapeutics to a "strong-buy" rating in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $74.67.

Corcept Therapeutics Stock Performance

CORT stock opened at $51.60 on Tuesday. Corcept Therapeutics has a fifty-two week low of $28.66 and a fifty-two week high of $91.00. The business's 50-day moving average is $39.14 and its two-hundred day moving average is $54.36. The company has a market cap of $5.54 billion, a price-to-earnings ratio of 147.43 and a beta of 0.36.

Insiders Place Their Bets

In other news, Director G Leonard Baker, Jr. purchased 100,000 shares of the company's stock in a transaction that occurred on Tuesday, March 17th. The stock was bought at an average cost of $33.14 per share, with a total value of $3,314,000.00. Following the completion of the purchase, the director owned 1,146,631 shares in the company, valued at approximately $37,999,351.34. This represents a 9.55% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Joseph K. Belanoff sold 26,198 shares of the stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total value of $1,311,733.86. Following the transaction, the chief executive officer directly owned 2,918,326 shares of the company's stock, valued at approximately $146,120,582.82. The trade was a 0.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 66,198 shares of company stock worth $2,851,169 over the last quarter. 20.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Corcept Therapeutics

Institutional investors have recently modified their holdings of the stock. Advisory Services Network LLC bought a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at approximately $25,000. Clearstead Advisors LLC lifted its stake in shares of Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company's stock valued at $26,000 after purchasing an additional 193 shares during the last quarter. Hantz Financial Services Inc. lifted its stake in shares of Corcept Therapeutics by 598.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 395 shares during the last quarter. Larson Financial Group LLC lifted its stake in shares of Corcept Therapeutics by 2,326.3% in the 3rd quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 442 shares during the last quarter. Finally, Gould Capital LLC lifted its stake in shares of Corcept Therapeutics by 50.0% in the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 200 shares during the last quarter. 93.61% of the stock is owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.